Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer

PURPOSE: Crizotinib is a potent, orally administered tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC). We report final results from PROFILE 1005, the largest clinical trial to date for an ALK inhibitor in AL...

Descripción completa

Detalles Bibliográficos
Autores principales: Blackhall, Fiona, Ross Camidge, D, Shaw, Alice T, Soria, Jean-Charles, Solomon, Benjamin J, Mok, Tony, Hirsh, Vera, Jänne, Pasi A, Shi, Yuankai, Yang, Pan-Chyr, Pas, Tommaso De, Hida, Toyoaki, Carpeño, Javier De Castro, Lanzalone, Silvana, Polli, Anna, Iyer, Shrividya, Reisman, Arlene, Wilner, Keith D, Kim, Dong-Wan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703388/
https://www.ncbi.nlm.nih.gov/pubmed/29209525
http://dx.doi.org/10.1136/esmoopen-2017-000219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703388/
https://www.ncbi.nlm.nih.gov/pubmed/29209525
http://dx.doi.org/10.1136/esmoopen-2017-000219

Ejemplares similares